Steve Chung, MD
Neurology · Phoenix, AZNPI 1942317359
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $473,795 of the $685,204 with a category attached, or 69.1%. 32 manufacturers reported payments, led by SK Life Science, Inc. at 26.2% of the total. Among neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,164 payments — averaging $588.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$180K
- UCB, Inc.$162K
- Jazz Pharmaceuticals Inc.$61K
- Eisai Inc.$61K
- Catalyst Pharmaceuticals, Inc.$53K
- Neurelis, Inc.$51K
- plus $117K from 26 others
Across 67 payments — averaging $1279.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$79K
- UCB, Inc.$7K
What the payments were for
- Consulting fees$114,29617%
- Speaking & faculty fees$473,79569%
- Travel & lodging$67,92210%
- Food & beverage$29,1924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 245 | $179,734 |
| UCB, Inc. | 292 | $162,288 |
| Jazz Pharmaceuticals Inc. | 85 | $60,844 |
| Eisai Inc. | 100 | $60,757 |
| Catalyst Pharmaceuticals, Inc. | 44 | $53,274 |
| Neurelis, Inc. | 79 | $50,878 |
| Sunovion Pharmaceuticals Inc. | 97 | $35,039 |
| UCB SA | 18 | $29,182 |
| Greenwich Biosciences, Inc. | 32 | $23,656 |
| Aquestive Therapeutics, Inc. | 23 | $10,992 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $9,174 |
| Lundbeck LLC | 4 | $3,312 |
| Medtronic(2 entities) | 26 | $2,738 |
| Livanova USA, Inc. | 31 | $997 |
| Neuropace, Inc. | 20 | $753 |
| AbbVie | 27 | $599 |
| Zogenix Inc. | 7 | $361 |
| Novartis | 1 | $125 |
| Monteris Medical Corporation | 1 | $103 |
| Acadia Pharmaceuticals Inc | 1 | $96 |
| Upsher-smith Laboratories LLC | 2 | $56 |
| Sumitomo Pharma America, Inc. | 4 | $48 |
| AstraZeneca | 3 | $47 |
| Genentech USA, Inc. | 1 | $24 |
| Argenx US, Inc. | 1 | $24 |
| Sanofi | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$685,204 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 43 | $259,883 |
| BriviactBrivaracetam | 162 | $239,258 |
| AptiomEslicarbazepine Acetate | 79 | $185,494 |
| XcopriCenobamate | 115 | $178,501 |
| FycompaPerampanel | 62 | $75,114 |
| Lacosamide | 205 | $51,785 |
| Clobazam | 167 | $50,036 |
| OnfiClobazam | 11 | $36,360 |
| KeppraLevetiracetam | 12 | $32,335 |
| VimpatLacosamide | 11 | $25,371 |
| Rufinamide | 11 | $19,026 |
| NayzilamMidazolam | 20 | $15,360 |
| ValtocoDiazepam | 11 | $11,624 |
| Levetiracetam | 257 | $10,542 |
| Felbamate | 11 | $7,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $162,288 | $279,989193 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $35,039 | $185,49479 claims |
| SK Life Science, Inc.Xcopri | $179,734 | $178,501115 claims |
| Eisai Inc.Fycompa | $60,757 | $75,11462 claims |
| Lundbeck LLCOnfi | $3,312 | $36,36011 claims |
| UCB SAKeppra | $29,182 | $32,33512 claims |
| Neurelis, Inc.Valtoco | $50,878 | $11,62411 claims |
| Upsher-smith Laboratories LLCTopiramate | $56 | $98690 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
- Joshua TobinPhoenix$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.